Azide-Doxorubicin Liposome (PEGylated) (CAT#: CLBD016LY)

Description
This formulation is Doxorubicin Liposome (PEGylated) with the azide group, which can react with an dibenzocyclooctyne (DBCO) by click chemistry. The conjugation chemistry is based on the reaction of the azide reagent with an DBCO linker to form a stable triazole. DBCO moiety can be on the antibody and azide moiety can be on liposome and vice versa.
Lipid Composition
HSPC, Cholesterol, DSPE-PEG(2000), DSPE-PEG(2000)-Azide
Encapsulated Drug
Doxorubicin
Buffer
Ammonium sulfate, pH 7.4
Storage
Store in dark at +4°C and do not freeze
Size
100 nm
Quantity
5mL (available in lyophilized powder)
Molecular Structure
Download
DataSheet MSDS
FAQs Published Data Customer Reviews Related Sections
  1. What is the molar concentration of the liposome?

    The molar concentration of the liposome is 21.58 mM.

  2. Why should buffers containing azides be avoided in the conjugation process?

    Buffers containing azides should be avoided as they can react with DBCO, interfering with the intended azide-DBCO click chemistry conjugation.

  3. How long should the reaction be incubated?

    Typical reaction times are less than 12 hours, but longer incubation can improve efficiency.

  4. What is the primary application of Azide-Doxorubicin Liposome (PEGylated)?

    It is mainly used in cancer research to enhance the delivery and efficacy of doxorubicin.

  5. What precautions should be taken during the conjugation?

    Ensure the buffer does not contain azides and maintain proper temperatures to avoid protein denaturation.

Azide-Doxorubicin Liposome (PEGylated)-fig1


Verification of antibody presence on the liposomes' surface.

This study investigates the site-specific conjugation of antibodies on the surface of liposomes. The researchers used bio-orthogonal copper-free click chemistry (SPAAC) to conjugate azide-functionalized antibodies to DBCO-functionalized liposomes. Flow cytometry results indicate that, using this approach, the antibodies were successfully and effectively conjugated to the liposome surface. Additionally, the quantity of attached antibodies was found to be proportional to the number of available DBCO groups on the liposomes. In this research, azide serves as an essential component of bio-orthogonal chemistry, enabling the selective and effective conjugation of antibodies to the liposome surface.

Gai, Meiyu, et al. "A bio-orthogonal functionalization strategy for site-specific coupling of antibodies on vesicle surfaces after self-assembly." Polymer Chemistry 11.2 (2020): 527-540.

Distributed under Open Access license CC BY 3.0, without modification.

  • Reduced Cytotoxicity
    The reduced cytotoxic effects on non-target cells improved the safety profile of our experimental treatments.
  • Improved Biodistribution
    The formulation ensured an even biodistribution, enhancing the therapeutic potential in our cancer models.
  • Minimized Immune Clearance
    The PEGylated liposomes were effectively evading the immune system, ensuring prolonged activity.
  • Reduced Experimental Variability
    Utilizing this formulation has significantly reduced the variability in our experimental results.
  • Enhanced Targeting Efficiency
    Utilizing Azide-Doxorubicin Liposome in our studies allowed us to achieve targeted drug delivery with minimal off-target effects.

Click the button below to contact us or submit your feedback about this product.

For Research Use Only. Not For Clinical Use

Online Inquiry

Advertisement